Online citations, reference lists, and bibliographies.
← Back to Search

Determination Of Dabigatran, Rivaroxaban And Apixaban By Ultra‐performance Liquid Chromatography – Tandem Mass Spectrometry (UPLC‐MS/MS) And Coagulation Assays For Therapy Monitoring Of Novel Direct Oral Anticoagulants

E. M. H. Schmitz, K. Boonen, D. J. A. den Heuvel, J. L. J. Dongen, M. W. M. Schellings, J. M. A. Emmen, F. Graaf, L. Brunsveld, D. Kerkhof
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Three novel direct oral anticoagulants (DOACs) have recently been registered by the Food and Drug Administration and European Medicines Agency Commission: dabigatran, rivaroxaban, and apixaban. To quantify DOACs in plasma, various dedicated coagulation assays have been developed.
This paper references
10.1160/TH11-10-0718
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
M. Huisman (2012)
10.1016/j.jpba.2011.09.018
UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.
X. Delavenne (2012)
10.1111/J.1365-2125.2007.02899.X
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
J. Stangier (2007)
10.1177/1076029612441859
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Y. C. Barrett (2013)
10.1160/TH09-11-0758
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
J. van Ryn (2010)
10.1093/europace/eur263
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents
J. Bassand (2012)
Coagula - tion parameters in patients receiving dabigatran etexilate or rivaroxaban : two observational studies in patients undergoing total hip or total knee replacement
G Freyburger (2006)
US Department of Health and Human Services, Food and Drug Administration
(2001)
Oral anticoagulant therapy : Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of
W Ageno
Study DVT Dose-Ranging - symptomatic deep vein thrombosis: the Einstein factor Xa inhibitor rivaroxaban in the treatment of patients with acute A dose-ranging study evaluating once-daily oral administration of the
A. Gallus (2013)
Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures
Ep10-A3 (2006)
10.1007/s11239-011-0622-5
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability
J. Harenberg (2011)
focused update of the ESC guidelines for the management of atrial fibrillation : an update of the 2010 ESC guidelines for the management of atrial fibrillation
MM Samama (2012)
10.1016/j.thromres.2011.06.031
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories.
L. Asmis (2012)
Physicians Evidence - Based Clinical Practice Guidelines
MV Huisman (2012)
Determination of dabigatran, rivaroxaban and apixaban using UPLC-MS/MS and comparison with coagulation assays for therapy monitoring
E. E. Schmitz (2014)
10.1007/s11239-011-0591-8
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor
R. Becker (2011)
10.1160/TH11-11-0804
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
J. Douxfils (2012)
10.1007/s11239-011-0551-3
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
P. Wong (2011)
10.1016/j.thromres.2011.01.001
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.
G. Freyburger (2011)
The Ecarin Chromogenic Assay – a new method for quantification of direct thrombin inhibitors like hirudin
A Calatzis (2003)
10.1160/TH13-04-0301
The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples.
G. Hapgood (2013)
10.1124/dmd.107.019083
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
S. Blech (2008)
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis
W. Ageno (2012)
10.1159/000081506
Ecarin Chromogenic Assay – A New Method for Quantitative Determination of Direct Thrombin Inhibitors Like Hirudin
U. Lange (2003)
10.1007/s00228-013-1550-4
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
J. Antovic (2013)
10.1007/s11239-013-0907-y
Measuring the anticoagulant effects of target specific oral anticoagulants—reasons, methods and current limitations
H. Mani (2013)
10.2165/00003088-200847050-00001
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate
J. Stangier (2008)
10.1111/jth.12308
Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross‐sectional pharmacodynamic study based on peak and trough plasma levels
E. Hawes (2013)
10.1111/J.1365-2125.2006.02667.X
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.
Karl-Heinz Liesenfeld (2006)
10.1309/Q0G21Y26UR0UHQ1A
Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
A. Calatzis (2008)
10.1160/TH12-12-0898
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.
J. Douxfils (2013)
Clinical and Laboratory
PA Wayne (2006)
10.1007/BF01062709
Plasminogen activator inhibitor 1: Molecular aspects and clinical importance
D. Vaughan (2005)
10.1182/blood-2008-05-160143
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
H. Buller (2008)
10.1016/j.jchromb.2008.07.015
Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
G. Rohde (2008)
10.1093/EUROPACE/EUS305
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.
A. Camm (2012)
10.1016/J.REC.2012.11.003
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
A. J. Camm (2013)
10.1515/CCLM.2011.134
Laboratory assessment of new anticoagulants
M. Samama (2011)
Measuring the anticoagu
H Mani (2012)
10.1160/TH13-03-0202
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.
J. Douxfils (2013)
10.1378/chest.11-2292
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
W. Ageno (2012)
10.1097/MBC.0b013e32834f1b0c
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
J. Stangier (2012)
10.1309/AJCPQOD9WFPEYY0H
Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful?
J. Curvers (2012)



This paper is referenced by
10.1371/journal.pone.0145478
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
J. Kuhn (2015)
10.1016/j.jss.2019.09.041
Medication Reconciliation and Patient Safety in Trauma: Applicability of Existing Strategies.
J. DeAntonio (2019)
10.1016/j.microc.2020.105336
A review on: analysis of the first oral, direct factor Xa inhibitor; Rivaroxaban
Noha M. Hosny (2020)
10.1016/J.TOXAC.2016.08.002
Dosage plasmatique de quatre anticoagulants directs par UHPLC/DAD
Béatrice. Leroy (2016)
10.1038/s41598-017-07939-6
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System
Masanobu Ishii (2017)
10.1016/j.thromres.2020.09.002
Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
Nicholas Jakowenko (2020)
10.22159/ijap.2017v9i5.20028
DEVELOPMENT AND VALIDATION OF HPTLC METHOD FOR DETERMINATION APIXABAN IN BULK AND TABLETS
Hemant K. Jain (2017)
10.1556/650.2017.30928
Az új orális antikoagulánsokkal történő kezelés laboratóriumi vonatkozásai
Zsuzsanna Bereczky (2017)
10.1016/j.thromres.2018.02.141
Comprehensive characteristics of the anticoagulant activity of dabigatran in relation to its plasma concentration.
W. Comuth (2018)
10.20510/UKJPB/4/I1/87842
A Simultaneous Monitoring of Coagulation Time and Fibrinogen via PiCT on QCM-D
Munawar Hussain (2016)
Laboratory testing for Direct Oral Anticoagulants ( DOACs ) : Are we ready ?
Dr. Rock LEUNG (2017)
10.1007/s00277-015-2407-y
Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban
O. Königsbrügge (2015)
10.1007/s40262-016-0485-1
Effect of Activated Charcoal on Rivaroxaban Complex Absorption
E. Ollier (2016)
10.1080/00365513.2017.1403037
Measurement of dabigatran: previously demonstrated Hemoclot® Thrombin Inhibitor assay reagent instability on Sysmex CS-2100i is no longer an issue
Willemijn J Comuth (2018)
10.1007/s11239-019-01981-z
Monitoring of low dabigatran concentrations: diagnostic performance at clinically relevant decision thresholds
F. Härtig (2019)
10.1016/j.bios.2017.12.043
QCM-D surpassing clinical standard for the dose administration of new oral anticoagulant in the patient of coagulation disorders.
Munawar Hussain (2018)
10.1007/s13631-017-0170-x
Determinazione degli anticoagulanti orali diretti in regime di urgenza
Lucia Terzuoli (2017)
10.1016/J.ACA.2019.03.061
Liquid chromatographic methods for the determination of direct oral anticoagulant drugs in biological samples: A critical review.
Filipa Gouveia (2019)
10.1101/651075
Detecting Direct Oral Anticoagulants in Trauma Patients using Liquid Chromatography-Mass Spectrometry: a Novel Approach to Medication Reconciliation
S. Jayaraman (2019)
10.1177/1060028018811657
Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator
P. Billoir (2019)
10.1016/j.thromres.2017.05.005
Determination of edoxaban equivalent concentrations in human plasma by an automated anti-factor Xa chromogenic assay.
L. He (2017)
The dose individualisation of oral anticoagulants
S. M. Saffian (2018)
10.1016/j.jchromb.2020.122095
A UHPLC-MS/MS method to simultaneously quantify apixaban, edoxaban and rivaroxaban in human plasma and breast milk: For emerging lactation studies.
Yating Zhao (2020)
10.1111/ejh.12942
Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients
Kathrine Jensen (2017)
10.1159/000375181
Accidental Thrombolysis in a Stroke Patient Receiving Apixaban
Felix Fluri (2015)
10.1371/journal.pone.0171272
Determination of rivaroxaban in patient’s plasma samples by anti-Xa chromogenic test associated to High Performance Liquid Chromatography tandem Mass Spectrometry (HPLC-MS/MS)
P. B. M. Derogis (2017)
10.1055/s-0035-1544158
Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants.
J. Harenberg (2015)
10.1007/s00059-017-4665-z
Antikoagulation bei Vorhofflimmern im Alter
Philipp Bahrmann (2017)
10.1007/s11239-018-1748-5
Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study
Tomáš Bolek (2018)
10.3233/JCB-189016
Rivaroxaban plasma levels by UPLC-MRM mass spectrometry in a routine laboratory and clinical interpretation
Johanna Schmidt (2019)
10.1039/C5RA00171D
A comprehensive study of apixaban's degradation pathways under stress conditions using liquid chromatography coupled to multistage mass spectrometry
P. Secrétan (2015)
10.1016/j.pathol.2016.07.008
Sensitivity of routine coagulation assays to direct oral anticoagulants: patient samples versus commercial drug-specific calibrators.
M. S. Lim (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar